BIIB – Biogen Inc. – Fundamental analysis, financial statements, key ratios, and fair value analysis

Biogen Inc.

Healthcare
Biotechnology
318.33
11.33
3.69%
383.83
257.52
Stock Current Price
Change
Change %
52 Week High
52 Week Low

Financial Ratios

Earnings per Share (EPS)15.3
EPS Estimate Currrent Qtr6.72
Book Value Per Share68.33
Market Cap 64 Billion
PE Ratio 19.1
Dividend YieldNA

Stock Yield

Stock Return 7 Days5.39%
Stock Return 15 Days-6.25%
Stock Return 30 Days -11.64%
Stock Return 3 Months-15.02%
Stock Return One Year-12.16%
Stock Return 3 Years-9.95%

Stock Technical Analysis

Relative Strengh Index (14)39.72
Average True Range (14)11.21
Momentum (14)-15.61
Simple Moving Average (14) -15.61
Time Series Forecast (14)282.01
Time Series Forecast (30) 327.56

Stock News

NewsSourcePublished
BRIEF-Samsung Biologics’ JV Samsung Bioepis Partners With Chinese Biopharma 3SBioYahoo Finance01/07/2019 00:24
All the Pre-JPM News Healthcare Investors Need to KnowYahoo Finance01/06/2019 15:00
See what the IHS Markit Score report has to say about Biogen Inc.Yahoo Finance01/05/2019 13:07
Biogen Begins Improved Dosing Regimen on Tysabri in Phase IIIYahoo Finance01/04/2019 23:13
REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds In Down MarketYahoo Finance01/04/2019 21:21
Biotechs lead broad market advance, XBI up 5%Seeking Alpha01/04/2019 13:11
Biogen doubles down on Alzheimer’s with new collaboration dealYahoo Finance01/04/2019 16:18
Biogen teams up with C4 Therapeutics in neurologySeeking Alpha01/04/2019 08:07
Biogen teams up with Skyhawk Therapeutics in neurological diseasesSeeking Alpha01/04/2019 08:00
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease TargetsYahoo Finance01/04/2019 12:31
Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological ConditionsYahoo Finance01/04/2019 12:30
Are Biogen Inc.’s (NASDAQ:BIIB) Interest Costs Too High?Yahoo Finance01/04/2019 11:48
Biogen commences late-stage study of extended interval dosing for MS med TysabriSeeking Alpha01/03/2019 08:01
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple SclerosisYahoo Finance01/03/2019 12:30
Biopharmas Restrained In Drug Pricing For 2019 — With These ExceptionsYahoo Finance01/02/2019 21:28
Drug makers OK with price inclusion in TV ads if done fairlySeeking Alpha01/02/2019 11:34
Top Picks 2019- Ionis Pharmaceuticals IONSYahoo Finance01/02/2019 11:00
The Humira Overhang Can’t Cast a Shadow on AbbVie Stock ForeverYahoo Finance12/27/2018 18:50

Financial Statements

index2014201520162017
Revenue10 Billion11 Billion11 Billion12 Billion
Cost of Revenue1 Billion1 Billion1 Billion2 Billion
Gross Profit9 Billion10 Billion10 Billion11 Billion
Gross Margin (%)87.93%88.48%87.08%86.72%
Selling General and Administrative Expense2 Billion2 Billion2 Billion2 Billion
Other operating expenses2 Billion3 Billion3 Billion4 Billion
Earning Before Interest and Taxes EBIT4 Billion5 Billion5 Billion5 Billion
EBIT/Operating Margin (%)40.45%43.74%43.15%40.72%
Interest Expense0000
Other non-operating expenses/income0000
Earnings before Tax4 Billion5 Billion5 Billion5 Billion
Income Tax Expense990 Million1 Billion1 Billion2 Billion
Net Income3 Billion4 Billion4 Billion3 Billion
Net Margin (%)30.25%32.95%32.34%20.69%
Earnings per share from operating income0.1081080.08653770.0788040.165129
Earnings per Diluted Share12.3715.3416.9311.92
Dividends per Basic Common Share0000
Weighted average number of shares outstanding237 Million231 Million219 Million213 Million
index2017 Q42018 Q12018 Q22018 Q3
Revenue3 Billion3 Billion3 Billion3 Billion
Cost of Revenue509 Million446 Million421 Million461 Million
Gross Profit3 Billion3 Billion3 Billion3 Billion
Gross Margin (%)84.60%85.76%87.46%86.60%
Selling General and Administrative Expense572 Million501 Million516 Million498 Million
Other operating expenses957 Million688 Million1 Billion666 Million
Earning Before Interest and Taxes EBIT1 Billion1 Billion1 Billion2 Billion
EBIT/Operating Margin (%)38.36%47.76%33.67%52.75%
Interest Expense0000
Other non-operating expenses/income0000
Earnings before Tax1 Billion1 Billion1 Billion2 Billion
Income Tax Expense2 Billion322 Million264 Million370 Million
Net Income-297 Million1 Billion867 Million1 Billion
Net Margin (%)-0.00%37.46%25.82%42.00%
Earnings per share from operating income3.091280.2301370.3120320.175668
Earnings per Diluted Share-15.544.187.15
Dividends per Basic Common Share0000
Weighted average number of shares outstanding216 Million212 Million207 Million202 Million
index2014201520162017
Cash and Equivalents1 Billion1 Billion2 Billion2 Billion
Trade and Non Trade Receivables2 Billion2 Billion2 Billion2 Billion
Inventory804 Million893 Million1 Billion903 Million
Other current assets3 Billion6 Billion8 Billion6 Billion
Current Assets5 Billion7 Billion9 Billion8 Billion
Total Non-Current Assets10 Billion13 Billion14 Billion16 Billion
Total Assets14 Billion20 Billion23 Billion24 Billion
Trade and Non Trade Payables229 Million267 Million280 Million396 Million
Other current liabilities2 Billion2 Billion3 Billion3 Billion
Current Liabilities2 Billion3 Billion3 Billion3 Billion
Liabilities Non Current1 Billion8 Billion7 Billion8 Billion
Accumulated Retained Earnings Deficit9 Billion12 Billion15 Billion16 Billion
Shareholder’s equity other2 Billion-3 Billion-3 Billion-3 Billion
Shareholders Equity11 Billion9 Billion12 Billion13 Billion
Noncontrolling interests4 Billion5 Billion7 Billion7 Billion
Total Assets14 Billion20 Billion23 Billion24 Billion
index2017 Q42018 Q12018 Q22018 Q3
Cash and Equivalents2 Billion4 Billion1 Billion2 Billion
Trade and Non Trade Receivables2 Billion2 Billion2 Billion3 Billion
Inventory903 Million891 Million932 Million917 Million
Other current assets6 Billion11 Billion5 Billion8 Billion
Current Assets8 Billion10 Billion7 Billion9 Billion
Total Non-Current Assets16 Billion16 Billion17 Billion17 Billion
Total Assets24 Billion26 Billion24 Billion25 Billion
Trade and Non Trade Payables396 Million346 Million296 Million342 Million
Other current liabilities3 Billion3 Billion3 Billion3 Billion
Current Liabilities3 Billion3 Billion3 Billion3 Billion
Liabilities Non Current8 Billion9 Billion9 Billion9 Billion
Accumulated Retained Earnings Deficit16 Billion17 Billion15 Billion17 Billion
Shareholder’s equity other-3 Billion-3 Billion-3 Billion-3 Billion
Shareholders Equity13 Billion14 Billion12 Billion14 Billion
Noncontrolling interests7 Billion6 Billion6 Billion6 Billion
Total Assets24 Billion26 Billion24 Billion25 Billion
index2014201520162017
Net Cash Flow from Operations3 Billion4 Billion5 Billion5 Billion
Capital Expenditure-316 Million-658 Million-728 Million-2 Billion
Net Cash Flow from Investing-2 Billion-5 Billion-2 Billion-3 Billion
Net Cash Flow from Financing-756 Million783 Million-1 Billion-2 Billion
Cash and Equivalents1 Billion1 Billion2 Billion2 Billion
index2017 Q42018 Q12018 Q22018 Q3
Net Cash Flow from Operations2 Billion1 Billion1 Billion2 Billion
Capital Expenditure-296 Million-195 Million-190 Million-163 Million
Net Cash Flow from Investing-770 Million1 Billion-1 Billion-619 Million
Net Cash Flow from Financing-708 Million-269 Million-3 Billion25 Million
Cash and Equivalents2 Billion4 Billion1 Billion2 Billion

Stock Price History

table